161 related articles for article (PubMed ID: 11248065)
1. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
Su GH; Bansal R; Murphy KM; Montgomery E; Yeo CJ; Hruban RH; Kern SE
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3254-7. PubMed ID: 11248065
[TBL] [Abstract][Full Text] [Related]
2. High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.
Sohn TA; Su GH; Ryu B; Yeo CJ; Kern SE
Ann Surg; 2001 May; 233(5):696-703. PubMed ID: 11323508
[TBL] [Abstract][Full Text] [Related]
3. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer.
Togashi Y; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Fujita Y; Kodera Y; Sakai K; Tomida S; Kitano M; Ito A; Kudo M; Nishio K
Mol Cancer; 2014 May; 13():126. PubMed ID: 24886203
[TBL] [Abstract][Full Text] [Related]
4. DPC4/SMAD4 gene alterations in human cancer, and their functional implications.
Schutte M
Ann Oncol; 1999; 10 Suppl 4():56-9. PubMed ID: 10436786
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
[TBL] [Abstract][Full Text] [Related]
6. The essential similarity of TGFbeta and activin receptor transcriptional responses in cancer cells.
Ryu B; Kern SE
Cancer Biol Ther; 2003; 2(2):164-70. PubMed ID: 12750556
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma.
Venkatasubbarao K; Ahmed MM; Mohiuddin M; Swiderski C; Lee E; Gower WR; Salhab KF; McGrath P; Strodel W; Freeman JW
Anticancer Res; 2000; 20(1A):43-51. PubMed ID: 10769633
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
[TBL] [Abstract][Full Text] [Related]
9. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells.
Grau AM; Zhang L; Wang W; Ruan S; Evans DB; Abbruzzese JL; Zhang W; Chiao PJ
Cancer Res; 1997 Sep; 57(18):3929-34. PubMed ID: 9307274
[TBL] [Abstract][Full Text] [Related]
10. DPC4 (SMAD4) mediates transforming growth factor-beta1 (TGF-beta1) induced growth inhibition and transcriptional response in breast tumour cells.
de Winter JP; Roelen BA; ten Dijke P; van der Burg B; van den Eijnden-van Raaij AJ
Oncogene; 1997 Apr; 14(16):1891-9. PubMed ID: 9150356
[TBL] [Abstract][Full Text] [Related]
11. [Alterations in DPC4 gene in pancreatic cancers].
Gu L; Chen J; Cui Q
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):293-5. PubMed ID: 11783110
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells.
Dai JL; Schutte M; Bansal RK; Wilentz RE; Sugar AY; Kern SE
Mol Carcinog; 1999 Sep; 26(1):37-43. PubMed ID: 10487520
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
14. Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers.
Hilgers W; Song JJ; Haye M; Hruban RR; Kern SE; Fearon ER
Genes Chromosomes Cancer; 2000 Apr; 27(4):353-7. PubMed ID: 10719364
[TBL] [Abstract][Full Text] [Related]
15. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.
Duda DG; Sunamura M; Lefter LP; Furukawa T; Yokoyama T; Yatsuoka T; Abe T; Inoue H; Motoi F; Egawa S; Matsuno S; Horii A
Oncogene; 2003 Oct; 22(44):6857-64. PubMed ID: 14534532
[TBL] [Abstract][Full Text] [Related]
16. [Alterations of DPC4/SMAD4/MADH4 gene detected in paraffin-embedded tissues of human pancreatic carcinomas].
Gu LJ; Chen J; Liu TH; Cui QC; Lu ZH; Li L; Gao J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Apr; 24(2):165-9. PubMed ID: 12905795
[TBL] [Abstract][Full Text] [Related]
17. SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res., 7: 4115-4121, 2001.
Liu F
Clin Cancer Res; 2001 Dec; 7(12):3853-6. PubMed ID: 11751474
[No Abstract] [Full Text] [Related]
18. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
20. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
